Lamotrigine And Borderline Personality Disorder: Investigating Long-Term Effectiveness

Registry ID
EUCTR2012-003136-23
Source registry
EUCTR
Status
Completed
Phase
PHASE4
Sponsor
Imperial College London
Start date
2012-11-27
Completion date
2016-09-22
Last update
2026-08-16

Conditions

Summary

The principal aim is to investigate the clinical and cost-effectiveness of adding lamotrigine to usual care for adults with Borderline Personality Disorder. To achieve this, we will: - Test whether adding lamotrigine to usual care for adults with Borderline Personality Disorder improves mental health over a 52 week period, in comparison to a placebo control. - Examine whether the addition of lamotrigine to usual care for adults with Borderline Personality Disorder improves social functioning and quality of life, reduces the incidence of suicidal behaviour, and lowers the amount of antipsychotic and other psychotropic medication that people are prescribed, in comparison to a placebo control. - Compare the incidence of side effects among those prescribed lamotrigine in addition to usual care for adults with Borderline Personality Disorder, in comparison to a placebo control. - Examine the cost, cost-utility and cost-effectiveness of adding lamotrigine to usual care for a

Locations

Related clinical trials

View on source registry